PD&ARNI
Recruiting
- Conditions
- Chronic kidney disease G5D Peritoneal dialysis patient with hypertension
- Registration Number
- jRCT1031250108
- Lead Sponsor
- Novartis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients who meet all of the following criteria will be included.
- Adult patients, regardless of gender, who visit the Department of Nephrology at Yamanashi University Hospital and have been undergoing peritoneal dialysis for at least six months.
- Peritoneal dialysis patients with hypertension.
- Patients who can provide written informed consent to participate in this study. Consent must be given by the individual.
Exclusion Criteria
1.Patients who meet the contraindications for sacubitril valsartan 2.Patients who were taking sacubitril valsartan before enrollment in the study 3.If a doctor determines that the person is unsuitable for the program
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - Changes in LVEF 3 and 6 months after taking Sacubitril Valsartan compared to before administration
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sacubitril-valsartan's effects on cardiac function in peritoneal dialysis patients with chronic kidney disease G5D and hypertension?
How does sacubitril-valsartan compare to standard-of-care RAAS inhibitors in managing hypertension and cardiac function in peritoneal dialysis patients with chronic kidney disease G5D?
Are there specific biomarkers that can predict response to sacubitril-valsartan in peritoneal dialysis patients with chronic kidney disease G5D and hypertension?
What are the known or potential adverse events associated with sacubitril-valsartan in peritoneal dialysis patients with chronic kidney disease G5D and hypertension, and how can they be managed?
What are the related compounds or combination approaches to sacubitril-valsartan for treating hypertension in peritoneal dialysis patients with chronic kidney disease G5D?